44 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Article Searches
These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest? https://www.fool.com/investing/2023/12/18/these-are-the-3-hottest-biopharma-trends-of-2024/?source=iedfolrf0000001 Dec 18, 2023 - 2024 is going to be a sizzler in the biopharma sector.
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry https://www.fool.com/investing/2023/12/21/weighing-their-chances-5-leading-healthcare-compan/?source=iedfolrf0000001 Dec 21, 2023 - Which weight-loss stocks are good buys today?
AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2024/02/08/astrazeneca-plc-azn-q4-2023-earnings-call-transcri/?source=iedfolrf0000001 Feb 08, 2024 - AZN earnings call for the period ending December 31, 2023.
AstraZeneca (AZN) to Discontinue Two Studies on Lokelma https://www.zacks.com/stock/news/2192314/astrazeneca-azn-to-discontinue-two-studies-on-lokelma?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2192314 Dec 01, 2023 - Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca https://www.zacks.com/stock/news/2193151/lilly-lly-gets-second-fda-nod-for-lymphoma-drug-jaypirca?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193151 Dec 04, 2023 - Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
Novartis (NVS) Gets FDA Nod for Rare Blood Disorder Drug https://www.zacks.com/stock/news/2194094/novartis-nvs-gets-fda-nod-for-rare-blood-disorder-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2194094 Dec 06, 2023 - Novartis (NVS) obtains FDA approval for Fabhalta, the first oral monotherapy for treating adults with PNH.
Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus https://www.zacks.com/stock/news/2195113/sanofi-sny-posts-upbeat-long-term-outlook-enhances-r-d-focus?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195113 Dec 07, 2023 - Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.
AstraZeneca (AZN) to Acquire Vaccine Maker Icosavax for $1.1B https://www.zacks.com/stock/news/2196741/astrazeneca-azn-to-acquire-vaccine-maker-icosavax-for-1-1b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196741 Dec 12, 2023 - AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Icosavax, for a total deal value of up to $1.1 billion.
The Zacks Analyst Blog Highlights Adobe, AstraZeneca, Intel, Morgan Stanley and EOG Resources https://www.zacks.com/stock/news/2198070/the-zacks-analyst-blog-highlights-adobe-astrazeneca-intel-morgan-stanley-and-eog-resources?cid=CS-ZC-FT-press_releases-2198070 Dec 14, 2023 - Adobe, AstraZeneca, Intel, Morgan Stanley and EOG Resources are part of the Zacks top Analyst Blog.
Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More https://www.zacks.com/stock/news/2198513/pharma-stock-roundup-pfe-issues-weak-2024-view-azn-to-buy-icosavax-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2198513 Dec 15, 2023 - Pfizer (PFE) issues a disappointing outlook for 2024. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax.

Pages: 12345

Page 1>